Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study

References

• Lai MM. RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus. J Virol. 2005;79:7951–7958.
   PubMed Web of Science ®Google Scholar
• Rizzetto M. Hepatitis D virus: introduction and epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021576.
   Google Scholar
• Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46:420–426.
   PubMed Web of Science ®Google Scholar
• Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int. 2011;31:7–21.
   PubMed Web of Science ®Google Scholar
• Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629–1638.
   PubMed Web of Science ®Google Scholar
• Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat. 2005;12:2–9.
   PubMed Web of Science ®Google Scholar
• Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006;26:805–810.
   PubMed Web of Science ®Google Scholar
• Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713–720.
   PubMed Web of Science ®Google Scholar
• Castelnau C, Le Gal F, Ripault M-P, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–735.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydin C, Dalekos G, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–331.
   PubMed Web of Science ®Google Scholar
• Karaca C, Soyer OM, Baran B, et al. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. 2013;18:561–566.
   PubMed Web of Science ®Google Scholar
• Kaymakoglu S, Karaca C, Demir K, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother. 2005;49:1135–1138.
   PubMed Web of Science ®Google Scholar
• Wolters LM, van Nunen AB, Honkoop P, et al. Lamivudine high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat. 2000;7:428–434.
   PubMed Web of Science ®Google Scholar
• Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–1749.
   PubMed Web of Science ®Google Scholar
• Lau DT-Y, Kleiner DE, Park Y, et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999;117:1229–1233.
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Bozkaya H, Karaaslan H, et al. A pilot study of two years of interferon in patient with chronic delta hepatitis. J Viral Hepat. 2007;14:812–816.
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.
   PubMed Web of Science ®Google Scholar
• Symonovsky V. The diagnosis of cirrhosis by high resolution ultrasound of the liver surface. Br J Radiol. 1999;72:29–34.
   PubMed Web of Science ®Google Scholar
• Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol. 2014;20:4300–4315.
   PubMed Web of Science ®Google Scholar
• Niro GA, Smedile A, Andriulli A, et al. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology. 1997;25:728–734.
   PubMed Web of Science ®Google Scholar
• Bulut Y, Bahcecioglu IH, Aygun C, et al. High genetic diversity of hepatitis delta virus in eastern Turkey. J Infect Dev Ctries. 2014;8:74–78.
   PubMed Web of Science ®Google Scholar
• Altuglu I, Ozacar T, Sertoz RY, et al. Hepatitis delta virus (HDV) genotypes in patients with chronic hepatitis: molecular epidemiology of HDV in Turkey. Int J Infect Dis. 2007;11:58–62.
   PubMed Web of Science ®Google Scholar
• Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40:93–104.
   PubMed Web of Science ®Google Scholar
• Ormeci N, Bölükbaş F, Erden E, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology. 2011;58:1648–1653.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Rijckborst V, Boucher CAB, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52:1251–1257.
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454–461.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–1109.
   PubMed Web of Science ®Google Scholar
• Keskin O, Wedemeyer H, Tüzün A, et al. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. Clin Gastroenterol Hepatol. 2015;13:2342–2349.
   PubMed Web of Science ®Google Scholar
• Manesis EK, Schina M, Le Gal F, et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther. 2007;12:381–388.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydin C, Ernst S, et al. 96 weeks of pegylated-interferonalpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Hepatology (Baltimore, MD). 2013;58:222A–3A.
   Google Scholar
• Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330:88–94.
   PubMed Web of Science ®Google Scholar